One proposed mechanism for this phenomenon is increased tumor immunogenicity due to impaired CD8+ T cell function (prior to ICB), which imparts a functional advantage to those CD8+ T cells reinvigorated by ICB [155]. This evidence concerns the gene CD8A and neoplasm.